公开(公告)号：US20240191294A1

公开(公告)日：2024-06-13

申请号：US18410502

申请日：2024-01-11

Applicant: FUJIFILM Corporation

Inventor： Kentaro NAKAMURA ,  Tsukasa KITAHASHI ,  Yuichi YOSHINO ,  Ryo KOGAWA

IPC: C12Q1/6876 ,  A61K35/28 ,  A61P19/02

CPC classification number: C12Q1/6876 ,  A61K35/28 ,  A61P19/02 ,  C12Q2600/158

Abstract: An object of the present invention is to provide such a quality management method for a cell that enables the sorting-out of a cell having drug efficacy, and a method of producing a cell using the quality management method. According to the present invention, there is provided a method that is a quality management method for a cell for a medical treatment or drug discovery, the method including managing a behavior of one or more specific protein molecules, which is essential for exhibiting a therapeutic effect due to a cell and managing an expression behavior of a related gene group that is characteristic of the cell.

公开(公告)号：US20190219386A1

公开(公告)日：2019-07-18

申请号：US16359289

申请日：2019-03-20

Applicant: FUJIFILM Corporation

Inventor： Hisao ARAI ,  Yi HU ,  Ken OKADA ,  Mayumi KATAYAMA ,  Tsukasa KITAHASHI

IPC: G01B11/24 ,  A61B5/00 ,  A61B5/107

CPC classification number: G01B11/24 ,  A61B5/0064 ,  A61B5/1077 ,  A61B5/1079 ,  A61B5/444 ,  A61B5/70 ,  A61B5/7445 ,  A61B2503/40

Abstract: A measuring device includes a measuring unit that measures the morphology of a convex portion, and a position fixing unit that includes an opening in which the convex portion is to be disposed and a fixing member which includes the opening at a center thereof and against which the periphery of the convex portion is to be pressed. The size of the opening of the position fixing unit is capable of being changed.

公开(公告)号：US20240299459A1

公开(公告)日：2024-09-12

申请号：US18590366

申请日：2024-02-28

Applicant: FUJIFILM Corporation ,  National University Corporation Tokyo Medical and Dental University

Inventor： Tsukasa KITAHASHI ,  Ryo KOGAWA ,  Kentaro NAKAMURA ,  Ichiro SEKIYA

IPC: A61K35/28 ,  A61P19/02 ,  C12N5/0775

CPC classification number: A61K35/28 ,  A61P19/02 ,  C12N5/0668

Abstract: An object of the present invention is to provide a therapeutic agent for arthrosis, which contains synovium-derived mesenchymal stem cells having a molecule essential for joint medical treatment, and a production method for the therapeutic agent for arthrosis. According to the present invention, there is provided a therapeutic agent for arthrosis, which contains synovium-derived mesenchymal stem cells having any one or more kinds of surface antigens of integrin β1 or platelet-derived growth factor receptor β.

公开(公告)号：US20180243214A1

公开(公告)日：2018-08-30

申请号：US15967970

申请日：2018-05-01

Applicant: FUJIFILM Corporation

Inventor： Tsukasa KITAHASHI ,  Shinji MIMA ,  Takeshi MATSUMOTO ,  Takahiro SEKIGUCHI ,  Mikinaga MORI

IPC: A61K9/127 ,  A61K31/7068 ,  A61K31/337 ,  A61K47/28 ,  A61K47/24 ,  A61P35/00

CPC classification number: A61K9/127 ,  A61K31/337 ,  A61K31/7068 ,  A61K47/24 ,  A61K47/28 ,  A61P35/00 ,  A61K2300/00

Abstract: An object of the present invention is to provide a tumor therapeutic agent and a kit which have superior antitumor effects as compared with gemcitabine, a taxane antitumor agent, and a combination therapy thereof which have been put on the market. According to the present invention, there is provided a tumor therapeutic agent obtained by combining a taxane antitumor agent with a liposome composition in which gemcitabine or a salt thereof is contained in a liposome.

公开(公告)号：US20210275453A1

公开(公告)日：2021-09-09

申请号：US17184928

申请日：2021-02-25

Applicant: FUJIFILM Corporation

Inventor： Tsukasa KITAHASHI ,  Shinji MIMA ,  Takeshi MATSUMOTO ,  Takahiro SEKIGUCHI ,  Mikinaga MORI

IPC: A61K9/127 ,  A61K47/24 ,  A61K47/28 ,  A61K31/337 ,  A61K31/7068 ,  A61P35/00

Abstract: An object of the present invention is to provide a tumor therapeutic agent and a kit which have superior antitumor effects as compared with gemcitabine, a taxane antitumor agent, and a combination therapy thereof which have been put on the market. According to the present invention, there is provided a tumor therapeutic agent obtained by combining a taxane antitumor agent with a liposome composition in which gemcitabine or a salt thereof is contained in a liposome.

公开(公告)号：US20190192546A1

公开(公告)日：2019-06-27

申请号：US16286930

申请日：2019-02-27

Applicant: FUJIFILM Corporation

Inventor： Yoshihide IWAKI ,  Tsukasa KITAHASHI ,  Shinji MIMA

IPC: A61K31/7068 ,  A61K31/337 ,  A61P35/00 ,  A61K47/42

CPC classification number: A61K31/7068 ,  A61K9/14 ,  A61K31/337 ,  A61K47/42 ,  A61P35/00 ,  A61P43/00

Abstract: An object of the present invention is to provide an anti-tumor agent and an anti-tumor kit which have superior anti-tumor effect as compared with a therapy with gemcitabine, paclitaxel or a combination thereof; as well as an anti-tumor effect enhancer. According to the present invention, provided is an anti-tumor agent including paclitaxel or a salt thereof and 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine or a salt or prodrug thereof.

公开(公告)号：US20180171324A1

公开(公告)日：2018-06-21

申请号：US15887083

申请日：2018-02-02

Applicant: FUJIFILM Corporation

Inventor： Kentaro NAKAMURA ,  Shinji MIMA ,  Tsukasa KITAHASHI ,  Chihaya KAKINUMA

IPC: C12N11/02 ,  A01K67/027 ,  C12N5/095 ,  A61K49/00

CPC classification number: C12N11/02 ,  A01K67/0271 ,  A01K2207/12 ,  A01K2207/15 ,  A01K2207/30 ,  A01K2227/105 ,  A01K2267/0331 ,  A61K35/13 ,  A61K35/28 ,  A61K49/0008 ,  A61L27/00 ,  C12N5/0695 ,  C12N2533/54 ,  G01N33/50

Abstract: An object of the present invention is to provide a non-human model animal rich in stromal tissue, a cell structure useful for producing the above-described non-human model animal, a method for evaluating a test substance in which the above-described non-human model animal is used, and a method for producing the above-described non-human model animal. According to the present invention, a cell structure is provided which contains a biocompatible macromolecular block and at least a cancer cell and a mesenchymal cell, and in which a plurality of the above-described biocompatible macromolecular blocks are arranged in gaps between a plurality of the above-described cells.